Iron Metabolism and Idiopathic Pulmonary Arterial Hypertension: New Insights from Bioinformatic Analysis.

Iron Metabolism and Idiopathic Pulmonary Arterial Hypertension: New Insights from Bioinformatic Analysis.
复制标题

DOI:
10.1155/2021/5669412
复制
发表时间:
2021
影响因子:
--
通讯作者:
Huang H
Huang H
中科院分区:
生物学3区
文献类型:
--
作者:
Zou HX;Qiu BQ;Lai SQ;Zhou XL;Gong CW;Wang LJ;Yuan MM;He AD;Liu JC;Huang H

文献摘要

参考文献

相似文献

Idiopathic pulmonary arterial hypertension (IPAH) is a rare vascular disease with a poor prognosis, and the mechanism of its development remains unclear. Further molecular pathology studies may contribute to a comprehensive understanding of IPAH and provide new insights into diagnostic markers and potential therapeutic targets. Iron deficiency has been reported in 43-63% of patients with IPAH and is associated with reduced exercise capacity and higher mortality, suggesting that dysregulated iron metabolism may play an unrecognized role in influencing the development of IPAH. In this study, we explored the regulatory mechanisms of iron metabolism in IPAH by bioinformatic analysis. The molecular function of iron metabolism-related genes (IMRGs) is mainly enriched in active transmembrane transporter activity, and they mainly affect the biological process of response to oxidative stress. Ferroptosis and fluid shear stress and atherosclerosis pathways may be the critical pathways regulating iron metabolism in IPAH. We further identified 7 key genes (BCL2, GCLM, MSMO1, SLC7A11, SRXN1, TSPAN5, and TXNRD1) and 5 of the key genes (BCL2, MSMO1, SLC7A11, TSPAN5, and TXNRD1) as target genes may be regulated by 6 dysregulated miRNAs (miR-483-5p, miR-27a-3p, miR-27b-3p, miR-26b-5p, miR-199a-5p, and miR-23b-3p) in IPAH. In addition, we predicted potential IPAH drugs—celastrol and cinnamaldehyde—that target iron metabolism based on our results. These results provide insights for further definition of the role of dysregulated iron metabolism in IPAH and contribute to a deeper understanding of the molecular mechanisms and potential therapeutic targets of IPAH.
DOI: 10.1164/rccm.201604-0886pp
发表时间: 2017-01-15
影响因子: 24.7
作者:
Chun, Hyung J.;Bonnet, Sebastien;Chan, Stephen Y.
通讯作者: Chan, Stephen Y.
DOI: 10.1158/0008-5472.can-12-1474
发表时间: 2012-11-01
期刊: CANCER RESEARCH
影响因子: 11.2
作者:
Hartikainen, Jaana M.;Tengstroem, Maria;Soini, Ylermi
通讯作者: Soini, Ylermi
DOI: 10.1183/13993003.00773-2015
发表时间: 2016-10-01
影响因子: 24.3
作者:
Dabral, Swati;Tian, Xia;Schermuly, Ralph Theo
通讯作者: Schermuly, Ralph Theo
DOI: 10.1111/j.2517-6161.1995.tb02031.x
发表时间: 1995-01-01
影响因子: 5.8
作者:
BENJAMINI, Y;HOCHBERG, Y
通讯作者: HOCHBERG, Y
DOI: 10.1183/13993003.01887-2018
发表时间: 2019-01-01
影响因子: 24.3
作者:
Humbert, Marc;Guignabert, Christophe;Rabinovitch, Marlene
通讯作者: Rabinovitch, Marlene